News

ITM and Radiopharm Forge Strategic Partnership for Isotope Supply

ITM and Radiopharm Forge Strategic Partnership for Isotope Supply

ITM and Radiopharm Forge Strategic Partnership for Isotope Supply

Garching, Germany and Sydney are abuzz with excitement over the recent development in the field of radiopharmaceuticals. ITM Isotope Technologies Munich SE (ITM), a premier radiopharmaceutical biotech company, has partnered with Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX), a clinical stage radiotherapeutics firm known for its innovative approach. This new agreement revolves around the supply of non-carrier-added Lutetium-177 (n.c.a. 177Lu), a crucial radioisotope for advancing cancer treatment methods.

Overview of the Supply Agreement

Under this strategic supply agreement, Radiopharm will leverage ITM’s n.c.a. 177Lu across various clinical applications. This supply is expected to bolster key development programs, including RAD 204, RAD 202, and RV01. Each of these programs targets solid tumors with groundbreaking approaches, utilizing n.c.a. 177Lu in combination with specialized targeting molecules. The ultimate goal is to deliver a precise therapeutic effect right to the tumor sites, thereby maximizing treatment efficacy while minimizing systemic exposure.

The Importance of Lutetium-177 in Cancer Therapy

Radiopharmaceuticals like n.c.a. 177Lu play a pivotal role in treating certain cancers due to their ability to emit beta radiation. This radiation is instrumental in damaging malignant cells selectively, therefore enhancing the effectiveness of treatments while reducing side effects for patients. The therapy involves linking the radioisotope to specific targeting molecules that hone in on cancer cells, making this partnership between ITM and Radiopharm a significant addition to the oncological therapy landscape.

Quote from Radiopharm's CEO

Riccardo Canevari, the CEO and Managing Director of Radiopharm Theranostics, shared his enthusiasm about the agreement, stating, "Ensuring supply of key isotopes continues to be a priority for our team, allowing us to accelerate our clinical programs. Lutetium-177 is imperative for three of our advanced assets, and this partnership with ITM underscores our commitment to quality and reliability in our clinical endeavors."

ITM's Commitment to Quality and Reliability

ITM’s n.c.a. 177Lu is not only market-approved but also recognized for its high purity, making it an essential element for oncological research and treatment. The firm holds a Drug Master File (DMF) accredited by the U.S. FDA, signifying confidence in the safety and efficacy of their products. Additionally, this radioisotope is marketed in the EU under the brand name EndolucinBeta, affirming its acceptance and integration into therapeutics.

CEO of ITM Speaks on the Partnership

Andrew Cavey, CEO of ITM, highlighted the company’s dedication to supply high-quality medical radioisotopes: "As the leading global manufacturer, our commitment extends towards supporting our partners like Radiopharm in developing improved cancer therapies. This reflects our shared vision to enhance treatment options for patients worldwide."

About ITM Isotope Technologies Munich SE

ITM is focused on revolutionizing cancer treatment through innovative radiopharmaceuticals tailored for challenging tumors. The company's philosophy is grounded in meeting patient and clinician needs by concentrating on superior development, production, and global supply of radiopharmaceuticals. ITM continues to push boundaries with a diverse oncology pipeline, including several phase 3 studies that integrate high-quality radioisotopes with advanced targeting technologies.

About Radiopharm Theranostics

Radiopharm is pioneering a suite of specialized radiopharmaceuticals aimed at addressing significant medical needs. With operations spanning ASX and NASDAQ, the company is developing cutting-edge therapeutic applications targeting various solid tumors, including those in the breast, lung, and brain. Radiopharm’s extensive clinical program encompasses several trials that promise to elevate treatment standards and patient outcomes significantly.

Frequently Asked Questions

What is the significance of the agreement between ITM and Radiopharm?

The partnership allows Radiopharm access to ITM's n.c.a. Lutetium-177, vital for advancing their cancer treatment pipeline.

What programs will benefit from this radioisotope supply?

Key programs like RAD 204, RAD 202, and RV01 will utilize ITM's n.c.a. Lutetium-177 in their clinical developments.

Why is Lutetium-177 important for cancer therapy?

Lutetium-177 emits therapeutic beta radiation that directly targets malignant cells, minimizing damage to surrounding healthy tissue.

How does ITM ensure the quality of its radioisotopes?

ITM holds a Drug Master File with the FDA and possesses marketing authorization in the EU, attesting to the high quality of its products.

What are the core values of ITM Isotope Technologies München SE?

ITM is committed to enhancing patient outcomes by delivering innovative radiopharmaceutical solutions tailored for complex tumors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 131

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 88

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 104

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 97

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 106

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 174

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Hexagon Agility Nets Record $100M Order from Certarus

Updated Category News Views 79

Hexagon Agility and Certarus: A Major Deal Secured There ain't nothing like landing a big fish in the business world, and Hexagon Agility just hooked a whopper. This major player in clean fuel solutions secured an order from Certarus worth a hefty $100 million. For those who keep tabs, that's Hexagon's largest order for Mobile Pipeline® modules to date, and it's all...

Continue Reading
Performance Food Group Co's Earnings: What to Expect

Updated Category News Views 111

Preparing for Performance Food Group Co's Earnings Report Performance Food Group Co PFGC is on the verge of releasing its latest quarterly earnings report. Investors are keen to know what to anticipate ahead of this significant announcement. Expectations for Earnings Performance Analysts anticipate that Performance Food Group Co will report an earnings per share (EPS) of...

Continue Reading
Innovative Collaboration Transforms Healthcare for Incarcerated Patients

Updated Category News Views 360

Innovative Partnership Shaping Correctional Healthcare Armor Health is embarking on a transformative journey in correctional healthcare through an exciting partnership with Antidote-AI, set to significantly enhance the services provided to incarcerated individuals. This collaboration brings advanced artificial intelligence (AI) capabilities to the forefront of a critical...

Continue Reading
Celebrating Innovation: A Journey Through 17 Years of Left Field Labs

Updated Category News Views 405

Left Field Labs Marks 17 Years of Innovation and Growth Left Field Labs, a creative technology agency within Stagwell (NASDAQ: STGW), celebrates its 17th anniversary with impressive revenue growth and a diverse global client base. This celebration highlights its commitment to delivering transformative digital experiences using advanced AI technologies. Transformative...

Continue Reading
Leadership Changes at Humphreys Capital Pave New Pathway

Updated Category News Views 465

Humphreys Capital's Leadership Transition Overview Humphreys Capital, a prominent institutional investment manager, has announced significant changes in its leadership team. This transition includes the appointment of Grant Humphreys as Chairman of the Board of Directors, succeeding his father, Kirk Humphreys, who will continue his involvement as Chairman Emeritus. Blair...

Continue Reading